National Exposure Research Laboratory, United States Environmental Protection Agency, Research Triangle Park, North Carolina 27709.
Agency for Toxic Substances and Disease Registry, Atlanta, Georgia 30341.
Toxicol Sci. 2018 Apr 1;162(2):341-348. doi: 10.1093/toxsci/kfy010.
The development and application of physiologically based pharmacokinetic (PBPK) models in chemical toxicology have grown steadily since their emergence in the 1980s. However, critical evaluation of PBPK models to support public health decision-making across federal agencies has thus far occurred for only a few environmental chemicals. In order to encourage decision-makers to embrace the critical role of PBPK modeling in risk assessment, several important challenges require immediate attention from the modeling community. The objective of this contemporary review is to highlight 3 of these challenges, including: (1) difficulties in recruiting peer reviewers with appropriate modeling expertise and experience; (2) lack of confidence in PBPK models for which no tissue/plasma concentration data exist for model evaluation; and (3) lack of transferability across modeling platforms. Several recommendations for addressing these 3 issues are provided to initiate dialog among members of the PBPK modeling community, as these issues must be overcome for the field of PBPK modeling to advance and for PBPK models to be more routinely applied in support of public health decision-making.
自 20 世纪 80 年代以来,生理药代动力学(PBPK)模型在毒理学中的发展和应用稳步增长。然而,到目前为止,只有少数环境化学物质对支持联邦机构公共卫生决策的 PBPK 模型进行了关键性评估。为了鼓励决策者在风险评估中接受 PBPK 建模的关键作用,建模界需要立即关注几个重要挑战。本综述的目的是强调其中的 3 个挑战,包括:(1)难以招募具有适当建模专业知识和经验的同行评审员;(2)对于没有组织/血浆浓度数据可用于模型评估的 PBPK 模型缺乏信心;以及(3)跨建模平台的可转移性缺乏。为了解决这 3 个问题,提出了一些建议,以便在 PBPK 建模界成员之间展开对话,因为必须克服这些问题,PBPK 建模领域才能取得进展,PBPK 模型才能更常规地应用于支持公共卫生决策。